Friday, December 26, 2014

Endo lobbying for Lidoderm protection, report says

Endo Health Solutions is lobbying both sides of the political aisle for protection of its Lidoderm patch as Congress moves forward with bills to fund the FDA, according to a N.Y. Times report.

Endo lobbying for Lidoderm protection, report says

Endo Health Solutions is lobbying both sides of the political aisle for protection of its Lidoderm patch as Congress moves forward with bills to fund the U.S. Food and Drug Administration, according to a report in Wednesday's New York Times.

The Times reported that Endo hired a former Democratic Congressman to lobby Democrats and a former aide to Republican Rep. Fred Upton (Mich.), who leads the House committee overseeing FDA authorization, to urge Republicans to write rules into the legislation that would require greater testing of some generic products.

Endo is based in Chadds Ford. The prescription lidoderm patch is used for treatment of after-shingles pain.

The lobbyists working the halls of Congress, in this episode, are Bart Stupak, a former Michigan Democratic House member, and William R. Nordwind, who worked more than a decade for Upton, to lobby for language that differentiates patches from tablets or capsules, which are most common delivery method for generics and branded drugs. According to the report, Endo wants enhanced - meaning more expensive and time consuming - testing of generic patches.

Stupak and Nordwind are partners at Venable L.L.P., a large law firm.

“I don’t talk about my clients,” Stupak said, according to the Times, which added that Endo spokesman Kevin Wiggins was equally uncommunicative on the topic.

Wiggins has not replied to a request by the Inquirer for comment.

Endo has been fighting to protect the Lidoderm franchise in other ways. Mylan and Watson have submitted applications for generic versions of Lidoderm. Endo was fighting Watson in court over the patent language. Before the judge in the case reached a decision, the two sides announced a settlement Tuesday that could put off when Watson would market its patch after getting FDA approval.

A link to the Times story is here.

A link to the Endo 8K filing with the SEC is here.

A link to the Endo-Watson agreement, as part of that SEC filing, is here.

David Sell
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Business Videos:
Also on Philly.com:
Stay Connected